NCT05176964 is a clinical trial of split-course HFRT in Rectal Cancer, sponsored by Fujian Medical University Union Hospital.

Who is sponsoring NCT05176964?

NCT05176964 is sponsored by Fujian Medical University Union Hospital.

What drugs are being tested in NCT05176964?

Interventions in NCT05176964: split-course HFRT, CAPOX chemotherapy, Tislelizumab.

What condition does NCT05176964 study?

NCT05176964 studies Rectal Cancer, Radiation Oncology.

Is NCT05176964 still recruiting?

NCT05176964 is currently status unknown. Last updated 25 September 2023.

Last reviewed 2023-09-25 · How we verify

NCT05176964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

Status unknown Last updated 25 September 2023

What this trial tests

trial testing split-course HFRT in Rectal Cancer in 50 participants. Status unknown.

Timeline

31 December 2021

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Fujian Medical University Union Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	31 December 2021
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

split-course HFRT
CAPOX chemotherapy — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Radiation Oncology — all drugs for Radiation Oncology →

Sponsor

Fujian Medical University Union Hospital

Who can join

Adults 18 to 70, any sex, with Rectal Cancer or Radiation Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The question of how to administer adequate chemotherapy and immunotherapy to synchronise hypofraction radiotherapy （HFRT） treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients with locally advanced rectal cancer (LARC).We aimed to study whether chemotherapy and tislelizumab plus split-course HFRT results in better outcomes in LARC patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
Veen T, Kanani A, Lea D, Søreide K. · · 2023 · cited 21× · PMID 37528319 · DOI 10.1007/s00262-023-03480-w
Therapeutic Management of Locally Advanced Rectal Cancer: Existing and Prospective Approaches.
Lișcu HD, Verga N, Atasiei DI, Ilie AT, et al · · 2025 · cited 9× · PMID 39941583 · DOI 10.3390/jcm14030912
Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
Chen JT, Zhou YW, Han TR, Wei JL, et al · · 2023 · cited 5× · PMID 38022667 · DOI 10.3389/fimmu.2023.1269341
Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial.
Zheng R, Wang BS, Li Z, Chi P, et al · · 2023 · cited 2× · PMID 36927585 · DOI 10.1136/bmjopen-2022-066976
Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives.
Fei J, Cai C, Wu W, Shen H, et al · · 2026 · PMID 41950929 · DOI 10.1016/j.xcrm.2026.102728

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Fujian Medical University Union Hospital trials

Trials by the same sponsor.

NCT07406815 — The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Inva · Phase 3 · not yet recruiting
NCT07444983 — Rezvilutamide for High-Risk Prostate Cancer After Surgery · NA · not yet recruiting
NCT07493070 — Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca · NA · active not recruiting
NCT07389889 — Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nod · NA · not yet recruiting
NCT07303231 — The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esoph · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05176964 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University Union Hospital
Last refreshed: 25 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing